Guggenheim raises target for Elevance Health stock to USD 460
Published on 10/15/2026 at 11:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Guggenheim lifted its Elevance Health target to USD 460 on October 12, 2026.
- Second-quarter revenue reached USD 49.83 billion on July 15, 2026.
- Elevance Health stock trades at EUR 383.05 at 10:49 a.m. CEST at Lang & Schwarz on October 15, 2026.
Elevance Health (ISIN US0367521038) was trading at EUR 383.05 at Lang & Schwarz on October 15, 2026, at 10:49 a.m. CEST. Guggenheim raised its price target from USD 455 to USD 460 on October 12, 2026, while maintaining a Buy rating, according to MarketBeat.
Why the target moved higher
The analyst update points to improved performance across Elevance Health's Medicaid, Medicare Advantage and Individual ACA businesses. The USD 5 increase reflects higher 2027 earnings estimates, while the Buy rating keeps the focus on operating recovery rather than a single quarterly result, as Investing.com reported on October 12, 2026.
For investors, the counter-factor is medical cost discipline. The same analyst discussion highlighted Medicaid rate adequacy, the durability of ACA margins and the potential for earnings growth across Medicare Advantage, commercial insurance and Carelon.
Three events set the path
On July 15, 2026, Elevance Health reported second-quarter revenue of USD 49.83 billion and adjusted earnings per share of USD 7.45, ahead of the USD 6.21 consensus estimate, according to MarketBeat. On September 8, 2026, the company reaffirmed adjusted 2026 earnings guidance of at least USD 27.00 per diluted share, as Quiver Quantitative reported. On October 12, 2026, Guggenheim raised its target to USD 460.
What date comes next
Elevance Health is scheduled to release third-quarter 2026 results on October 21, 2026, at 6:00 a.m. EDT, followed by a management webcast at 8:30 a.m. EDT, according to the company's release carried by Elevance Health. The report will test whether the improved Medicaid, Medicare Advantage and ACA trends cited by Guggenheim are visible in reported results.
Stock value and upcoming results
The current euro quotation gives German investors a direct trading reference ahead of the report, while the analyst target places attention on future earnings execution. The company's second-quarter revenue was USD 49.83 billion and its adjusted earnings guidance stood at least USD 27.00 per diluted share for fiscal year 2026.
Elevance Health was trading at EUR 383.05 at Lang & Schwarz on October 15, 2026 at 10:49 a.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.
Elevance Health stock facts
- Company: Elevance Health Inc.
- ISIN: US0367521038
- Ticker: ELV
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 15, 2026, 10:49 a.m. CEST): EUR 383.05
- Market capitalization: USD 92.8 billion (as of October 14, 2026)
- Sector / Industry: Healthcare / Medical - Healthcare Plans
- Index membership: S&P 500
- Next earnings date: October 21, 2026
Market context: Market report S&P 500.
